Escherichia coli (E. coli) is the main cause of Gram-negative bacterial peritonitis among peritoneal dialysis patients. According to the 2016 update of the International Society for Peritoneal Dialysis Peritonitis Recommendations, drug susceptibilities of specific organisms should be regularly monitored. The aim of this study was to examine the evolution of antimicrobial resistance of E. coli peritonitis from 2006 to 2018. Two hundred and fifty-three episodes of E. coli peritonitis were enrolled in our study, corresponding to a rate of 0.024 episodes per patient-year. According to drug sensitivity test results, isolates were most sensitive to carbapenems, followed by cefmetazole, piperacillin/tazobactam, cefotetan and amikacin, with an overall rate of more than 90% in both cohorts. Cefazolin and ciprofloxacin resistance increased significantly from 2006–2011 to 2012–2018. Conversely, cefepime and ceftazidime resistance decreased significantly. The extended-spectrum β-lactamase (ESBL) rate fluctuated from 34.7% in 2006–2011 to 46.8% in 2012–2018. Compared with the ESBL-negative strains, ESBL-producing E. coli were more likely be resistant to ampicillin, ampicillin/sulbactam, cephalosporins, quinolones, aminoglycosides, furadantin and sulfamethoxazole and accounted for over 50% of the drug resistance. In the correlation analysis, E. coli displayed significantly increased resistance to cefazolin and ciprofloxacin, a finding correlated with ESBL production (r = 0.883 and 0.276 respectively, p < 0.001 and p = 0.003). In conclusion, the rate of E. coli peritonitis declined stably in recent years, but the resistance to antimicrobial was high.

1. Choi, P, Nemati, E, Banerjee, A, et al. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43: 103–111.
Google Scholar | Crossref | Medline2. Johnson, DW, Dent, H, Hawley, CM, et al. Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis 2009; 53(2): 290–297.
Google Scholar | Crossref | Medline3. Boudville, N, Kemp, A, Clayton, P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012; 23(8): 1398–1405.
Google Scholar | Crossref | Medline4. Yip, T, Tse, KC, Lam, MF, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. Perit Dial Int 2006; 26(2): 191–197.
Google Scholar | SAGE Journals5. Li, PK, Szeto, CC, Piraino, B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36(5): 481–508.
Google Scholar | SAGE Journals6. Thaden, JT, Fowler, VG, Sexton, DJ, et al. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol 2016; 37(1): 49–54.
Google Scholar | Crossref | Medline7. Kassakian, SZ, Mermel, LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control 2014; 3(1): 9.
Google Scholar | Crossref | Medline8. Hu, FP, Guo, Y, Zhu, DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect 2016; 22(Suppl 1): S9–S14.
Google Scholar | Crossref | Medline9. Zhang, D, Liao, K, Zhong, X, et al. Analysis of species distribution and antibiotic susceptibility trends of 1172 bacterial uropathogens isolated in urine cultures on an outpatient basis. Chin J Nephrol 2020; 36(7):519–525.
Google Scholar10. Xiao, Y, Hang, Y, Chen, Y, et al. A retrospective analysis of risk factors and patient outcomes of bloodstream infection with extended-spectrum β-lactamase-producing Escherichia coli in a Chinese tertiary hospital. Infect Drug Resist 2020; 13: 4289–4296.
Google Scholar | Crossref | Medline11. Harris, PN, Tambyah, PA, Paterson, DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015; 15(4): 475–485.
Google Scholar | Crossref | Medline12. Kussmann, M, Ferth, A, Obermüller, M, et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Sci Rep 2019; 9(1): 6512.
Google Scholar | Crossref | Medline13. Thammishetti, V, Kaul, A, Bhadauria, DS, et al. A retrospective analysis of etiology and outcomes of refractory CAPD peritonitis in a tertiary care center from North India. Perit Dial Int 2018; 38(6): 441–446.
Google Scholar | SAGE Journals14. Feng, X, Yang, X, Yi, C, et al. Escherichia coli peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a south China dialysis center. Perit Dial Int 2013; 34: 308–316.
Google Scholar | SAGE Journals